Please assess the completion status of the following clinical trial:

Trial Title: Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female sex~2. At least 18 years old at MBC diagnosis~3. Diagnosis of MBC at any point in patient history~   1. ICD-9 (174.x, 175.x) or ICD-10 (C50.xx) diagnosis of BC~  2. Confirmation of metastatic disease~  3. At least 2 document clinical visits~  4. Evidence of stage IV or recurrent MBC with a metastatic diagnosis date on or after 2011, as confirmed by unstructured clinical documents~4. HR+/HER2-~   1. HR+: ER+ or PR+ test before or up to 60 days after MBC diagnosis~  2. HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, FISH positive/amplified, Positive NOS) before or up to 60 days after MBC diagnosis~5. Palbociclib + AI or letrozole as first-line therapy for MBC during the period from February/2015 through August /31/2018 (or 3 months prior to study cut-off date) to allow for a possible minimum follow-up time of 90 days until the study cutoff date. AI was administered within (±) 28 days of Palbociclib index date.~Exclusion Criteria:~1. Evidence of prior treatment with other CDK4/6I (Ribociclib or Abemaciclib), AI (Letrozole, Exemestane, and Anastrazole), Tamoxifen, Raloxifene, Toremifene, or Fulvestrant for MBC~2. First structured activity greater than 90 days after MBC diagnostic date~3. Treatment with a CDK4/6 inhibitor as part of a clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + an aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
- Palbociclib + Letrozole (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
- Letrozole (Type: None): Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.

Based on this trial design, predict the completion outcome and termination type (if applicable).